+

WO2003066024A1 - Formulation pharmaceutique comprenant une suspension aqueuse d'un derive d'androstane pour le traitement d'etats inflammatoires et allergiques - Google Patents

Formulation pharmaceutique comprenant une suspension aqueuse d'un derive d'androstane pour le traitement d'etats inflammatoires et allergiques Download PDF

Info

Publication number
WO2003066024A1
WO2003066024A1 PCT/GB2003/000504 GB0300504W WO03066024A1 WO 2003066024 A1 WO2003066024 A1 WO 2003066024A1 GB 0300504 W GB0300504 W GB 0300504W WO 03066024 A1 WO03066024 A1 WO 03066024A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
compound
formula
formulation according
particles
Prior art date
Application number
PCT/GB2003/000504
Other languages
English (en)
Inventor
Keith Biggadike
Ian Buxton
Steven John Coote
Rosalyn Kay Nice
Kenton Lewis Reed
Amyn Sayani
Avinash Chander Sharma
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27732225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003066024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to EP03737365.1A priority Critical patent/EP1478340B1/fr
Priority to AU2003244506A priority patent/AU2003244506A1/en
Priority to ES03737365T priority patent/ES2699507T3/es
Priority to US10/502,902 priority patent/US20050164996A1/en
Priority to EP18193195.7A priority patent/EP3510994A1/fr
Priority to JP2003565449A priority patent/JP4838493B2/ja
Publication of WO2003066024A1 publication Critical patent/WO2003066024A1/fr
Priority to US12/858,940 priority patent/US20100311706A1/en
Priority to US13/370,493 priority patent/US20120142651A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Definitions

  • the present invention relates to pharmaceutical formulations containing an anti- inflammatory and anti-allergic compound of the androstane series and to processes for their preparation.
  • the present invention also relates to therapeutic uses thereof, particularly for the treatment of inflammatory and allergic conditions.
  • Glucocorticoids which have anti-inflammatory properties are known and are widely used for the treatment of inflammatory disorders or diseases such as asthma and rhinitis.
  • US Patent 4335121 discloses 6 , 9 ⁇ -Difluoro-17 ⁇ -(1- oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (known by the generic name of fluticasone propionate) and derivatives thereof.
  • fluticasone propionate known by the generic name of fluticasone propionate
  • glucocorticoids include suppression of the Hypothalamic- Pituitary-Adrenal (HPA) axis, effects on bone growth in children and on bone density in the elderly, ocular complications (cataract formation and glaucoma) and skin atrophy.
  • HPA Hypothalamic- Pituitary-Adrenal
  • Certain glucocorticoid compounds also have complex paths of metabolism wherein the production of active metabolites may make the pharmacodynamics and pharmacokinetics of such compounds difficult to understand.
  • the medicament To formulate an effective pharmaceutical nasal composition, the medicament must be delivered readily to all portions of the nasal cavities (the target tissues) where it performs its pharmacological function. Additionally, the medicament should remain in contact with the target tissues for relatively long periods of time. The longer the medicament remains in contact with the target tissues, the medicament must be capable of resisting those forces in the nasal passages that function to remove particles from the nose. Such forces, referred to as 'mucociliary clearance', are recognised as being extremely effective in removing particles from the nose in a rapid manner, for example, within 10-30 minutes from the time the particles enter the nose.
  • a nasal composition must not contain ingredients which cause the user discomfort, that it has satisfactory stability and shelf-life properties, and that it does not include constituents that are considered to be detrimental to the environment, for example ozone depletors.
  • glucocorticoids the potential for any undesirable side effects should preferably be minimised.
  • a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I)
  • the formulation will contain one or more suspending agents.
  • the formulation will contain one or more preservatives.
  • the formulation will contain one or more wetting agents.
  • the formulation will contain one or more isotonicity adjusting agents.
  • a pharmaceutical formulation which comprises: (i) an aqueous suspension of particulate compound of formula (I) or a solvate thereof;
  • the formulations of the present invention may be stabilised by appropriate selection of pH.
  • the pH will be adjusted to between 4.5 and 7.5, preferably between 5.0 and 7.0, especially around 6.0.
  • Examples of pharmaceutically acceptable materials which can be used to adjust the pH of the formulation include hydrochloric acid and sodium hydroxide.
  • the pH of the formulation will be adjusted using hydrochloric acid.
  • the aqueous component is preferably a high grade quality of water, most preferably purified water.
  • the active compound of formula (I) or solvate thereof will suitably have a mass mean diameter (MMD) of less than 20 ⁇ m, preferably between 0.5-1 O ⁇ m, especially between 1-5 ⁇ m. If particle size reduction is necessary, this may be achieved by techniques such as micr ⁇ nisation and/or microfluidisation.
  • MMD mass mean diameter
  • Particularly preferred MMDs are between 2-4 ⁇ m.
  • particle size reduction may be achieved by micronisation.
  • particle size reduction may be achieved by microfluidisation.
  • the particles will be crystalline, prepared for example by a process which comprises mixing in a continuous flow cell in the presence of ultrasonic radiation a flowing solution of compound of formula (I) or solvate thereof as medicament in a liquid solvent with a flowing liquid antisolvent for said medicament (as described in International Patent Application PCT.GB99.04368).
  • a pharmaceutically effective amount of particulate compound of formula (I) or solvate thereof is present within the formulation, in an amount which is preferably between 0.005% and 1% (w/w), preferably between 0.01% and 0.5% (w/w), especially 0.05- 0.1% (w/w) based on the total weight of the formulation.
  • 50 ⁇ l of suspension will contain 50 ⁇ g of compound of formula (I) or solvate thereof.
  • suspending agents examples include carboxymethylcellulose, veegum, tragacanth, bentonite, methylcellulose and polyethylene glycols.
  • the suspending agent will be microcrystalline cellulose and carboxy methylcellulose sodium, most preferably used as the branded product Avicel RC591 (which typically contains 87-91% microcrystalline cellulose and 9 -13% carboxy methylcellulose s ⁇ diun ⁇ ).
  • Particulate microcrystalline cellulose will preferably have a particle size in the range 1 to 100 ⁇ m.
  • Avicel RC591 acts as a suspending agent by imparting thixotropic properties to the formulation, wherein the formulation may become a stable suspension upon being stirred, shaken or otherwise disturbed.
  • the thixotropic nature of the suspending agent will ensure that the formulation assumes a gel like appearance at rest, wherein the particulate medicament is dispersed and suspended substantially uniformly, characterised by a high viscosity value.
  • the viscosity of the formulation will preferably decrease to such a level to enable it to flow readily through the spray device and exit as a spray of fine particles in a mist. These particles will then be capable of infiltrating the mucosal surfaces of the anterior regions of the nose (frontal nasal cavities), the frontal sinus, the maxillary sinuses and the turbinates which overlie the conchas of the nasal cavities.
  • the viscosity of the formulation will preferably increase to a sufficient level to assume its gel-like form and resist being cleared from the nasal passages by the inherent mucocillary forces that are present in the nasal cavities.
  • the formulation of the present invention comprises a suspending agent
  • a suspending agent it will be desirably added in a suitable amount to achieve this function, preferably the suspending agent will be present within the formulation in an amount of between 0.1 and 5% (w/w), especially 1.5% (w/w), based on the total weight of the formulation.
  • the formulation of the present invention should be protected from microbial contamination and growth by inclusion of a preservative.
  • pharmaceutically acceptable anti-microbial agents or preservatives that can be used in the formulation include quaternary ammonium compounds (eg. benzalkonium chloride, benzethonium chloride, cetrimide and cetylpyridinium chloride), mercurial agents (eg. phenylmercuric nitrate, phenylmercuric acetate and thimerosal), alcoholic agents (eg. chlorobutanol, phenylethyl alcohol and benzyl alcohol), antibacterial esters (eg.
  • quaternary ammonium compounds eg. benzalkonium chloride, benzethonium chloride, cetrimide and cetylpyridinium chloride
  • mercurial agents eg. phenylmercuric nitrate, phenylmercuric acetate and thimerosal
  • alcoholic agents
  • the preservative will comprise disodium edetate (EDTA), which will preferably be present within the formulation in an amount of between 0.001 and 1% (w/w), especially around 0.015% (w/w), based on the total weight of the formulation.
  • EDTA disodium edetate
  • the preservative will comprise benzalkonium chloride (BKC), which will preferably be present within the formulation in an amount of between 0.001 and 1% (w/w), especially around 0.015% (w/w), based on the total weight of the formulation.
  • BKC benzalkonium chloride
  • the preservative comprises disodium edetate and benzalkonium chloride or disodium edetate and potassium sorbate, particularly disodium edetate and benzalkonium chloride.
  • Formulations eg nasal formulations which contain a suspended medicament (such as a compound of formula (I) or a solvate thereof) will preferably contain a pharmaceutically acceptable wetting agent which functions to wet the particles of medicament to facilitate dispersion thereof in the aqueous phase of the composition.
  • a pharmaceutically acceptable wetting agent which functions to wet the particles of medicament to facilitate dispersion thereof in the aqueous phase of the composition.
  • the amount of wetting agent used will not cause foaming of the dispersion during mixing.
  • wetting agents any agent which is effective in wetting the particles and which is pharmaceutically acceptable can be used.
  • wetting agents that can be used are fatty alcohols, esters and ethers.
  • the wetting agent will be a hydrophilic, non-ionic surfactant, most preferably polyoxyethylene (20) sorbitan monooleate (supplied as the branded product Polysorbate 80).
  • the formulation of the present invention comprises a wetting agent
  • the wetting agent will be present within the formulation in an amount of between 0.001 and 0.05% (w/w), especially 0.025% (w/w), based on the total weight of the formulation.
  • an isotonicity adjusting agent is to achieve isotonicity with body fluids eg fluids of the nasal cavity, resulting in reduced levels of irritancy associated with many nasal formulations.
  • suitable isotonicity adjusting agents are sodium chloride, dextrose and calcium chloride.
  • the isotonicity adjusting agent will be dextrose, most preferably used as anhydrous dextrose.
  • the formulation of the present invention comprises an isotonicity adjusting agent it will be desirably added in a sufficient quantity to achieve this function, preferably the isotonicity adjusting agent will be present within the formulation in an amount of between 0.1 and 10% (w/w), especially 5.0% w/w, based on the total weight of the formulation.
  • the compound of formula (I) or solvate thereof is present within the formulation in an amount between 0.005% and 1 % (w/w), based on the total weight of the formulation.
  • the suspending agent is microcrystalline cellulose and carboxy methylcellulose sodium
  • the preservative is EDTA and benzalkonium chloride
  • the wetting agent is polyoxyethylene (20) sorbitan monooleate
  • the isotonicity adjusting agent is dextrose.
  • the compound of formula (I) or a solvate thereof and formulations thereof have potentially beneficial anti-inflammatory or anti-allergic effects, particularly upon topical administration to the nose, demonstrated by, for example, its ability to bind to the glucocorticoid receptor and to illicit a response via that receptor, with long acting effect.
  • formulations according to the invention are useful in the treatment of inflammatory and/or allergic disorders of the nose, especially in once-per-day therapy.
  • Formulations according to the invention may be prepared by combining the ingredients in water. If necessary the pH may be adjusted as a final step. Formulations so prepared may then be filled into the receptacle.
  • Aqueous formulations of the invention may also be employed for rectal, aural, otic, oral, topical or parenteral administration or administration by inhalation for the treatment of other local inflammatory conditions (eg dermatitis, asthma, chronic obstructive pulmonary disease (COPD) and the like).
  • formulations of the invention may be administered to the lung by nebulisation.
  • Such formulations may employ excipients (eg preservatives, buffers and the like) appropriate for the route of administration.
  • Examples of disease states in which the compound of formula (I) has utility include inflammatory and/or allergic conditions of the nasal passages such as rhinitis eg seasonal and perennial rhinitis as well as other local inflammatory conditions such as asthma, COPD and dermatitis.
  • Preferable means for applying the formulation of the present invention to the nasal passages is by use of a pre-compression pump, such as a VP3, VP7 or modifications, model manufactured by Valois SA.
  • a pre-compression pump such as a VP3, VP7 or modifications, model manufactured by Valois SA.
  • Advantages of pumps of this type are beneficial as they will ensure that the formulation is not released or atomised until a sufficient force has been applied, otherwise smaller doses may be applied.
  • these pre-compression pumps may be used with a bottle (glass or plastic) capable of holding 8-5 ml of a formulation. Each spray will typically deliver 50-1 OO ⁇ l of such a formulation, therefore, the device is capable of providing at least 100 metered doses.
  • a suitable dosing regime for the formulation of the present invention when administered to the nose would be for the patient to inhale slowly through the nose subsequent to the nasal cavity being cleared. During inhalation the formulation would be applied to one nostril while the other is manually compressed. This procedure would then be repeated for the other nostril.
  • one or two inhalations per nostril would be administered by the above procedure up to three times each day, ideally once daily.
  • formulations comprising a compound of formula (1) or solvate thereof are useful in human or veterinary medicine, in particular as an anti- inflammatory and anti-allergic agent.
  • a formulation comprising the compound of formula (I) or solvate thereof for use in human or veterinary medicine, particularly in the treatment of patients with inflammatory and/or allergic conditions.
  • a formulation comprising the compound of formula (I) or solvate thereof for the manufacture of a medicament for the treatment of patients with inflammatory and/or allergic conditions.
  • a method for the treatment of a human or animal subject with an inflammatory and/or allergic condition comprises administering to said human or animal subject an effective amount of a formulation comprising the compound of formula (I) or solvate thereof.
  • the compound of formula (I) is long-acting, therefore preferably the compound will be delivered once-per-day and the dose will be selected so that the compound has a therapeutic effect in the treatment of respiratory disorders (eg rhinitis) over 24 hours or more.
  • respiratory disorders eg rhinitis
  • compositions according to the invention may also be used in combination with another therapeutically active agent, for example, an anti-histamine or an anti-allergic.
  • another therapeutically active agent for example, an anti-histamine or an anti-allergic.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof together with another therapeutically active agent, for example, an anti- hista fmine or an anti-allergic.
  • anti-histamines examples include methapyrilene or loratadine.
  • NSAIDs eg. PDE4 inhibitors, leukotriene antagonists, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a agonists
  • antiinfective agents eg. antibiotics, antivirals
  • the PDE4-specific inhibitor useful in this aspect of the invention may be any compound that is known to inhibit the PDE4 enzyme or which is discovered to act as a PDE4 inhibitor, and which are only PDE4 inhibitors, not compounds which inhibit other members of the PDE family as well as PDE4.
  • a PDE4 inhibitor which has an IC50 ratio of about 0.1 or greater as regards the IC50 for the PDE4 catalytic form which binds rolipram with a high affinity divided by the IC50 for the form which binds rolipram with a low affinity.
  • the cAMP catalytic site which binds R and S rolipram with a low affinity is denominated the "low affinity” binding site (LPDE 4) and the other form of this catalytic site which binds rolipram with a high affinity is denominated the "high affinity” binding site (HPDE 4).
  • LPDE 4 low affinity binding site
  • HPDE 4 high affinity binding site
  • the pharmaceutical formulation according to the invention may further comprise one or more excipients.
  • excipient as used herein, it is meant to mean substantially inert materials that are nontoxic and do not interact with other components of a composition in a deleterious manner including, but not limited to, pharmaceutical grades of: carbohydrates, organic and inorganic salts, polymers, amino acids, phospholipids, wetting agents, emulsifiers, surfactants, poloxamers, pluronics, and ion exchange resins, and combinations thereof, a non-exhaustive list of examples of which are provided below:
  • Carbohydrates including: monosaccharides, such as, but not limited to, fructose; disaccharides, such as, but not limited to lactose, and combinations and derivatives thereof; polysaccharides, such as, but not limited to, cellulose and combinations and derivatives thereof; oligosaccharides, such as, but not limited to, dextrins, and combinations and derivatives thereof; polyols, such as but not limited to sorbitol, and combinations and derivatives thereof;
  • Organic and inorganic salts including but not limited to sodium or calcium phosphates, magnesium stearate, and combinations and derivatives thereof;
  • Polymers including: natural biodegradable protein polymers including, but not limited to, gelatin and combinations and derivatives thereof;
  • Natural biodegradable polysaccharide polymers including, but not limited to, chitin and starch, crosslinked starch, and combinations and derivatives thereof;
  • Semisynthetic biodegradable polymers including, but not limited to, derivatives of chitosan;
  • Synthetic biodegradable polymers including but not limited to polyethylene glycols (PEG), polylactic acid (PLA), synthetic polymers including but not limited to polyvinyl alcohol and combinations and derivatives thereof; Amino acids including but not limited to including non-polar amino acids, such as leucine and combinations and derivatives thereof;
  • Phospholipids including lecithins and combinations and derivatives thereof;
  • wetting agents/ Surfactants/Emulsifiers including, but not limited to gum acacia, cholesterol, fatty acids including, combinations and derivatives thereof;
  • Poloxamers/ Pluronics including but not limited to poloxamer 188, Pluronic®
  • Ion exchange resins including but not limited to amberlite IR120 and combinations and derivatives thereof; and combinations of the noted excipients.
  • the individual compounds of such combinations may be administered either sequentially in separate pharmaceutical compositions as well as simultaneously in combined pharmaceutical formulations.
  • Preferably additional therapeutically active ingredients are suspended in the formulation together with the compound of formula (I).
  • Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.
  • a process for preparing a compound of formula (I) comprises alkylation of a thioacid of formula (II)
  • the compound of formula (II) rriay be reacted with a compound of formula FCH 2 L wherein L represents a leaving group (eg a halogen atom, a mesyl or tosyl group or the like) for example, an appropriate fluoromethyl halide under . standard conditions.
  • L represents a leaving group (eg a halogen atom, a mesyl or tosyl group or the like) for example, an appropriate fluoromethyl halide under . standard conditions.
  • the fluoromethyl halide reagent is bromofluoromethane.
  • the compound of formula (II) is employed as a salt, particularly the salt with diisopropylethylamine.
  • the compound of formula (II) or a salt thereof is treated with bromofluoromethane optionally in the presence of a phase transfer catalyst.
  • a preferred solvent is methylacetate, or more preferably ethylacetate, optionally in the presence of water. The presence of water improves solubility of both starting material and product and the use of a phase transfer catalyst results in an increased rate of reaction.
  • phase transfer catalysts examples include (but are not restricted to) tetrabutylammonium bromide, tetrabutylammonium chloride, benzyltributylammonium bromide, benzyltributylammonium chloride, benzyltriethylammonium bromide, methyltributylammonium chloride and methyltrioctylammonium chloride.
  • THF has also successfully been employed as solvent for the reaction wherein the presence of a phase transfer catalyst again provides a significantly faster reaction rate.
  • the product present in an organic phase is washed firstly with aqueous acid eg dilute HCI in order to remove amine compounds such as triethylamine and diisopropylethylamine and then with aqueous base eg sodium bicarbonate in order to remove any unreacted precursor compound of formula (II).
  • aqueous acid eg dilute HCI
  • amine compounds such as triethylamine and diisopropylethylamine
  • aqueous base eg sodium bicarbonate
  • Compound of formula (I) in unsolvated form may be prepared by a process comprising:
  • step (a) Crystallising the compound of formula (I) in the presence of a non-solvating solvent such as ethanol, methanol, water, ethyl acetate, toluene, methylisobutylketone or mixtures thereof; or (b) Desolvating a compound of formula (I) in solvated form (eg in the form of a solvate with acetone, isopropanol, methylethylketone, DMF or tetrahydrofuran) eg by heating.
  • the desolvation will generally be performed at a temperature exceeding 50°C preferably at a temperature exceeding 100°C. Generally heating will be performed under vacuum.
  • Forms 1 , 2 and 3 crystalline polymorphic forms
  • XRPD X-ray diffraction
  • Form 2 Peaks at around 18.4 and 21.5 degrees
  • Form 3 Peaks at around 18.6 and 19.2 degrees 2Theta.
  • Unsolvated polymorph Form 1 appears likely to be the thermodynamically most stable form since Forms 2 and 3 are converted into Form 1 on heating. Polymorph Form 1 is preferred.
  • the compound of formula (I) in unsolvated polymorph Form 1 substantially to be in the form of equant or substantially equant particles.
  • Substantially equant particles have dimensions in the X, Y and Z dimensions which are similar in length.
  • Another aspect of the present invention provides compounds of formula (I) substantially in the form of equant or substantially equant particles.
  • the equant particles will be in the form of tetragonal bipyramidal or substantially tetragonal bipyramidal particles.
  • Tetragonal bipyramidal particles of Form 1 polymorph have surprisingly been found to produce relatively consistent sized particles after micronisation, which appears to be independent of the drying process prior to micronisation.
  • the tetragonal bipyramidal particles possess good flow properties, good bulk density, and are easily isolated from suspension by filtration.
  • Another aspect of the present invention provides compounds of formula (I) substantially in the form of acicular particles.
  • Acicular particles of Form 1 have surprisingly been found to produce relatively varying sized particle distribution after micronisation, and particle sizes which, on average, are larger than those produced from micronisation of tetragonal bipyramidal particles. In certain circumstances where this size profile of micronised product is preferred, then acicular particles will be preferred. It may be that the micronised product produced from acicular particles will result in lower systemic exposure to the active compound.
  • a process for preparing a compound of formula (I) as unsolvated Form 1 polymorph comprises dissolving compound of formula (I) in methylisobutylketone, ethyl acetate or methyl acetate and producing compound of formula (I) as unsolvated Form 1 by addition of a non-solvating anti-solvent such as iso-octane or toluene.
  • the compound of formula (I) may be dissolved in ethyl acetate and compound of formula (I) as unsolvated Form 1 polymorph may be obtained by addition of toluene as anti-solvent.
  • the ethyl acetate solution is hot and once the toluene has been added the mixture is distilled to reduce the content of ethyl acetate.
  • the compound of formula (I) may be dissolved in methylisobutylketone and compound of formula (I) as unsolvated Form 1 polymorph may be obtained by addition of isooctane as anti- solvent
  • Compound of formula (I) in solvated form may be prepared by crystallising the compound of formula (I) from a solvating solvent such as acetone, propan-2-ol, ethylacetate or tetrahydrofuran (THF).
  • a solvating solvent such as acetone, propan-2-ol, ethylacetate or tetrahydrofuran (THF).
  • the compound of formula (I) will be employed in unsolvated form, typically unsolvated Form 1.
  • a process for the preparation of a compound of formula (I), substantially in the form of equant or substantially equant particles which process comprises dissolving a compound of formula (I) in a suitable solvating solvent and crystallising the compound
  • Preferred solvating agents are acetone, propan-2-ol, ethylacetate or tetrahydrofuran, more preferably acetone or propan-2-ol.
  • the compound of formula (I) is preferably substantially in the form of tetragonal bipyramidel particles.
  • the step typically comprises the addition of a reagent suitable for performing the esterification eg an activated derivative of 2-furoic acid such as an activated ester or preferably a 2-furoyl halide eg 2-furoyl chloride (employed in at least 2 times molar quantity relative to the compound of formula (III)) in the presence of an organic base eg triethylamine.
  • a reagent suitable for performing the esterification eg an activated derivative of 2-furoic acid such as an activated ester or preferably a 2-furoyl halide eg 2-furoyl chloride (employed in at least 2 times molar quantity relative to the compound of formula (III)) in the presence of an organic base eg triethylamine.
  • the second mole of 2-furoyl chloride reacts with the thioacid moiety in the compound of formula (III) and needs to be removed eg by reaction with an amine such as diethylamine.
  • This method suffers disadvantages, however, in that the resultant compound of formula (II) is hot readily purified of contamination with the by-product 2- furoyldiethylamide. We have therefore invented several improved processes for performing this conversion.
  • step (b) removal of the sulphur-linked 2-furoyl moiety from compound of formula (IIA) by reaction of the product of step (a) with an organic primary or secondary amine base capable of forming a water soluble 2-furoyl amide.
  • step (d) when the product of step (b) is dissolved in a substantially water immiscible organic solvent, purifying the compound of formula (II) by washing out the amide by-product from step (b) with an aqueous wash, or (c2) when the product of step (b) is dissolved in a water miscible solvent, purifying the compound of formula (II) by treating the product of step (b) with an aqueous medium so as to precipitate out pure compound of formula (II) or a salt thereof;
  • the activated derivative of 2-furoic acid may be an activated ester of 2-furoic acid, but is more preferably a 2-furoyl halide, especially 2-furoyl chloride.
  • a suitable solvent for this reaction is ethylacetate or methylacetate (preferably methylacetate) (when step (d) may be followed) or acetone (when step (c2) may be followed).
  • an organic base eg triethylamine will be present.
  • the organic base is diethanolamine.
  • the base may suitably be dissolved in a solvent eg methanol.
  • steps (a) and (b) will be performed at reduced temperature eg between 0 and 5°C.
  • the aqueous wash may be water, however the use of brine results in higher yields and is therefore preferred.
  • the aqueous medium is for example a dilute aqueous acid such as dilute HCI.
  • the activated derivative of 2-furoic acid may be an activated ester of 2-furoic acid, but is more preferably a 2-furoyl halide, especially 2-furoyl chloride.
  • a suitable solvent for his step is acetone. Normally an organic base eg triethylamine will be present.
  • a suitable solvent is DMF or dimethylacetamide. Normally an organic base eg triethylamine will be present.
  • steps (a) and (b) will be performed at reduced temperature eg between 0 and 5°C. The product may be isolated by treatment with acid and washing with water.
  • the compound of formula (II) may advantageously be isolated in the form of a solid crystalline salt.
  • the preferred salt is a salt formed with a base such as triethylamine, 2,4,6-trimethylpyridine, diisopropylethylamine or N-ethylpiperidine.
  • Such salt forms of compound of formula (II) are more stable, more readily filtered and dried and can be isolated in higher purity than the free thioacid.
  • the most preferred salt is the salt formed with diisopropylethylamine.
  • the triethylamine salt is also of interest.
  • Compounds of formula (III) may be prepared in accordance with procedures described in GB 2088877B. Compounds of formula (III) may also be prepared by a process comprising the following steps:
  • Step (a) comprises oxidation of a solution containing the compound of formula (V).
  • step (a) will be performed in the presence of a solvent comprising methanol, water, tetrahydrofuran, dioxan or diethylene glygol dimethylether.
  • a solvent comprising methanol, water, tetrahydrofuran, dioxan or diethylene glygol dimethylether.
  • preferred solvents are methanol, water or tetrahydrofuran, and more preferably are water or tetrahydrofuran, especially water and tetrahydrofuran as solvent.
  • Dioxan and diethylene glygol dimethylether are also preferred solvents which may optionally (and preferably) be employed together with water.
  • the solvent will be present in an amount of between 3 and 10vol relative to the amount of the starting material (1wt.), more preferably between 4 and 6 vol., especially 5 vol.
  • the oxidising agent is present in an amount of 1-9 molar equivalents relative to the amount of the starting material.
  • the oxidising agent may be present in an amount of between 1.1 and 10wt. relative to the amount of the starting material (1wt), more preferably between 1.1 and 3wt., especially 3wt.
  • the oxidation step will comprise the use of a chemical oxidising agent.
  • the oxidising agent will be periodic acid or iodic acid or a salt thereof. Most preferably, the oxidising agent will be periodic acid or sodium periodate, especially periodic acid.
  • the oxidation step may comprise any suitable oxidation reaction, eg one which utilises air and/or oxygen. When the oxidation reaction utilises air and/or oxygen, the solvent used in said reaction will preferably be methanol.
  • step (a) will involve incubating the reagents at room temperature or a little warmer, say around 25°C eg for 2 hours.
  • the compound of formula (IV) may be isolated by recrystallisation from the reaction mixture by addition of an anti-solvent.
  • a suitable anti-solvent for compound of formula (IV) is water. Surprisingly we have discovered that it is highly desirable to control the conditions under which the compound of formula (IV) is precipitated by addition of anti-solvent eg water. When the recrystallisation is performed using chilled water (eg water/ice mixture at a temperature of 0-5°C) although better anti-solvent properties may be expected we have found that the crystalline product produced is very voluminous, resembles a soft gel and is very difficult to filter. Without being limited by theory we believe that this low density product contains a large amount of solvated solvent within the crystal lattice.
  • Step (b) will typically comprise the addition of a reagent suitable for converting a carboxylic acid to a carbothioic acid eg using hydrogen sulphide gas together with a suitable coupling agent eg carbonyldiimidazole (CDI) in the presence of a suitable solvent eg dimethylformamide.
  • a suitable coupling agent eg carbonyldiimidazole (CDI)
  • CDI carbonyldiimidazole
  • a suitable solvent eg dimethylformamide.
  • the advantages of the formulation of the compound of formula (I) according to the invention may include the fact that the formulations demonstrate excellent anti- inflammatory properties, with predictable pharmacokinetic and pharmacodynamic behaviour, with an attractive side-effect profile, rapid onset of action, long duration of action, and are compatible with a convenient regime of treatment in human patients, in particular being amendable to once-per day dosing. Further advantages may include the fact that the formulation has desirable physical and chemical properties which allow for ready manufacture and storage.
  • a container comprising a pharmaceutical formulation according to the invention.
  • a device adapted for intranasal delivery of a pharmaceutical formulation comprising such a container
  • the formulation will be dispensed from a vessel fitted with a suitable pre- compression pump and nasal actuator, adapted to dispense 50 or 100 ⁇ l per actuation, preferably 50 ⁇ l
  • LCMS was conducted on a Supelcosil LCABZ+PLUS column (3.3 cm x 4.6 mm ID) eluting with 0.1% HCO 2 H and 0.01 M ammonium acetate in water (solvent A), and 0.05% HCO 2 H 5% water in acetonitrile (solvent B), using the following elution gradient 0-0.7 min 0%B, 0.7-4.2 min 100%B, 4.2-5.3 min 0%B, 5.3-5.5 min 0%B at a flow rate of 3 ml/min.
  • the mass spectra were recorded on a Fiso ⁇ s VG Platform spectrometer using electrospray positive and negative mode (ES+ve and ES-ve).
  • 2-Furoyl chloride 25ml is added and the mixture stirred at 0-5°C for 1 hour.
  • a solution of diethanolamine (52.8g) in methanol (50ml) is added and the mixture stirred at 0-5°C for at least 2 hours.
  • Dilute hydrochloric acid approximately 1 M, 550ml is added maintaining a reaction temperature below 15°C and the mixture stirred at 15°C.
  • the organic phase is separated and the aqueous phase is back extracted with methyl acetate (2x250ml). All of the organic phases are combined, washed sequentially with brine (5 x 250ml) and treated with di-isopropylethylamine (30ml).
  • the reaction mixture is • concentrated by distillation at atmospheric pressure to an approximate volume of 250ml and cooled to 25-30°C (crystallisation of the desired product normally occurs during distillation/subsequent cooling).
  • Tertiary butyl methyl ether (TBME) 500ml is added, the slurry further cooled and aged at 0-5°C for at least 10 minutes.
  • the product is filtered off, washed with chilled TBME (2x200ml) and dried under vacuum at approximately 40-50°C (75.3g, 98.7%).
  • a mobile suspension of Intermediate 1 (12.61g, 19.8mmol) in ethyl acetate (230ml) and water (50ml) is treated with a phase transfer catalyst (benzyltributylammonium chloride, 10mol%), cooled to 3°C and treated with bromofluoromethane (1.10ml, 19.5mrnol, 0.98 equivalents), washing in ith prechilled (0°C) ethyl acetate (EtOAc) (20ml). The suspension is stirred overnight, allowing to warm to 17°C.
  • a phase transfer catalyst benzyltributylammonium chloride, 10mol
  • bromofluoromethane (1.10ml, 19.5mrnol, 0.98 equivalents
  • EtOAc ethyl acetate
  • the aqueous layer is separated and the organic phase is sequentially washed with 1 M HCI (50ml), 1%w/v NaHCO 3 solution (3x50ml) and water (2x50ml).
  • the ethylacetate solution is distilled at atmospheric pressure until the distillate reaches a temperature of approximately 73°C at which point toluene (150ml) is added. Distillation is continued at atmospheric pressure until all remaining EtOAc has been removed (approximate distillate temperature 103°C).
  • the resultant suspension is cooled and aged at ⁇ 10°C and filtered off.
  • the solution is concentrated to ca lOvols a distillation at atmospheric pressure.
  • Propan-2-ol (10vols) is added.
  • the solution is seeded with the propan-2-ol solvate of 6 ⁇ , 9 ⁇ -Difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy- 16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (0.01wt) suspended in propan-2-ol (ca 0.03vols).
  • the suspension is adjusted to 50+ 5 ° and aged for ca 5 mins (until crystallisation is established).
  • the suspension is concentrated once again to ca 10vols.
  • the product is heated under vacuum at 105 to 115°C for at least 12 hours to give tetragonal bipyramidal particles of unsolvated Form 1 of the active compound.
  • Pharmacological activity was assessed in a functional in vitro assay of glucocorticoid agonist activity which is generally predictive of anti-inflammatory or anti-allergic activity in vivo.
  • the functional assay was based on that described by KP.Ray et al., Biochem J. (1997), 328, 707-715.
  • A549 cells stably transfected with a reporter gene containing the NF- ⁇ B responsive elements from the ELAM gene promoter coupled to sPAP (secreted alkaline phosphatase) were treated with test compounds at appropriate doses for 1 hour at 37°C.
  • the cells were then stimulated with tumour necrosis factor (TNF, 10ng/ml) for 16 hours, at which time the amount of alkaline phosphatase produced is measured by a standard colourimetric assay.
  • TNF tumour necrosis factor
  • Dose response curves were constructed from which ECa, values were estimated.
  • the glucocorticoid receptor can function in at least two distinct mechanisms, by upregulating gene expression through the direct binding of GR to specific sequences in gene promotors, and by downregulating gene expression that is being driven by other transcription factors (such as NFKB or AP-1) through their direct interaction with GR.
  • the first cell line contains the firefly luciferase reporter gene under the control of a synthetic promoter that specifically responds to activation of the transcription factor NFKB when stimulated with TNF ⁇ .
  • the second cell line contains the renilla luciferase reporter gene under the control of a synthetic promotor that comprises 3 copies of the consensus glucocorticoid response element, and which responds to direct stimulation by glucocorticoids.
  • Anaesthetised pigs (2) were dosed intra-tracheally with a homogenous mixture of compound (I) (1rhg) and fluticasone propionate (1mg) as a dry powder blend in lactose (10% w/w). Serial blood samples were taken for up to 8h following dosing. Plasma levels of compound (I) and fluticasone propionate were determined following extraction and analysis using LC-MS/MS methodology, the lower limits of quantitation of the methods were 10 and 20pg/mL for compound (I) and fluticasone propionate respectively. Using these methods compound (I) was quantifiable up to 2 hours after dosing and fluticasone propionate was quantifiable up to 8 hours after dosing.
  • Plasma half-life data obtained from IV dosing (0.1mg/kg) was used to calculate AUC (0-inf) values for compound (I). This compensates for the plasma profile of Compound (I) only being defined up to 2 hours after an IT dose and removes any bias due to limited data between compound (I) and fluticasone propionate.
  • Example 1 Nasal formulation containing 6 ⁇ . 9 ⁇ -Difluoro-17 ⁇ -f(2- furanylcarbonyPoxyl-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1.4-diene-17 ⁇ - carbothioic acid S-fluoromethyl ester
  • a formulation for intfanasal delivery was prepared with ingredients as follows: 6 ⁇ , 9 ⁇ -Difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo- androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (prepared according to
  • EDTA 0.015% w/w water to 100% in a total amount suitable for 120 actuations and the formulation was filled into a bottle (plastic or glass) fitted with a suitable pre-compression pump and nasal actuator, adapted to dispense 50 or 100 ⁇ l per actuation, preferably 50 ⁇ l
  • the formulation was prepared following the following protocol:
  • a formulation for intranasal delivery was prepared with ingredients as follows: 6 ⁇ , 9 ⁇ -Difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy-16 ⁇ -methyl-3-ox ⁇ - ar ⁇ drosta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (prepared according to
  • EDTA 0.015% w/w water to 100% in a total amount suitable for 120 actuations and the formulation was filled into a bottle (plastic or glass) fitted with a suitable pre-compression pump and nasal actuator, adapted to dispense 50 or 100 ⁇ l per actuation, preferably 50 ⁇ l.
  • Example 3 Nasal formulation containing 6 ⁇ . 9 ⁇ -Difluoro-17 ⁇ -[Y2- furanylcarbonyl)o ⁇ y]-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1 ,4-diene-17 ⁇ - carbothioic acid S-fluoromethyl ester
  • a formulation for intranasal delivery was prepared with ingredients as follows: 6 ⁇ , 9 ⁇ - Difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1 ,4- diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (prepared according to intermediate 3, micronised to MMD ,1.5 ⁇ m) 0.1 % w/w Polysorbate 80 0.025% w/w
  • the formulation was prepared following the different protocol below: Part A
  • Example 3 Stability studies on Example 3 showed it to be stable up to 3 months at 40°C (measurements were not taken beyond this time). The particle size of the active material has also been observed not to change significantly.
  • Fig. 1 shows an exploded view of a nasal inhaler suitable for use in accord with the invention
  • a nasal inhaler device 5 comprising a body 6 a container 3 and a nasal pump 8.
  • the device further comprises a protective end cap 7 having an inner surface 4 for engagement with the body 6 to protect the dispensing nozzle 11.
  • the body 6 is made from a plastic material and defines a housing 9 and a dispensing nozzle 11.
  • the housing 9 defines a cavity formed by a side wall and a first end wall and a second end wall 14.
  • the dispensing nozzle 11 is connected to and extends away from the second end wall 14 and has an external tapering form.
  • the dispensing nozzle 11 has a longitudinally extending orifice defined by an ⁇ tiet tube extending towards the cavity 10.
  • An annular abutment is formed within the orifice part way along the outlet tube. The annular abutment defines a small aperture through which fluid can flow in use.
  • the nasal pump 8 comprises a hollow casing 30 defining a reservoir containing several doses of the fluid nasal formulation to be dispensed and a plunger slidably engaged within the hollow casing 30.
  • a suitable nasal pump is described in US-A-4,964,069 incorporated herein by reference.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une formulation pharmaceutique qui comprend une suspension aqueuse d'un composé particulaire représenté par la formule (I) ou un solvate de celui-ci.
PCT/GB2003/000504 2000-08-05 2003-02-04 Formulation pharmaceutique comprenant une suspension aqueuse d'un derive d'androstane pour le traitement d'etats inflammatoires et allergiques WO2003066024A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP03737365.1A EP1478340B1 (fr) 2002-02-04 2003-02-04 Formulation pharmaceutique comprenant une suspension aqueuse d'un dérivé d'androstane pour le traitement d'états inflammatoires et allergiques
AU2003244506A AU2003244506A1 (en) 2002-02-04 2003-02-04 Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions
ES03737365T ES2699507T3 (es) 2002-02-04 2003-02-04 Composición farmacéutica que comprende una suspensión acuosa de un derivado de androstano para el tratamiento de afecciones inflamatorias y alérgicas
US10/502,902 US20050164996A1 (en) 2000-08-05 2003-02-04 Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions
EP18193195.7A EP3510994A1 (fr) 2002-02-04 2003-02-04 Formulation pharmaceutique comprenant une suspension aqueuse d'un dérivé d'androstane pour le traitement d'états inflammatoires et allergiques
JP2003565449A JP4838493B2 (ja) 2002-02-04 2003-02-04 炎症性およびアレルギー性状態の治療のためのアンドロスタン誘導体の水性懸濁物を含む医薬製剤
US12/858,940 US20100311706A1 (en) 2002-02-04 2010-08-18 Method of treatment of allergic rhinitis
US13/370,493 US20120142651A1 (en) 2002-02-04 2012-02-10 Method of treatment of allergic rhinitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/067,020 2002-02-04
US10/067,020 US6858596B2 (en) 2000-08-05 2002-02-04 Formulation containing anti-inflammatory androstane derivative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/067,020 Continuation-In-Part US6858596B2 (en) 2000-08-05 2002-02-04 Formulation containing anti-inflammatory androstane derivative

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP18193195.7A Previously-Filed-Application EP3510994A1 (fr) 2002-02-04 2003-02-04 Formulation pharmaceutique comprenant une suspension aqueuse d'un dérivé d'androstane pour le traitement d'états inflammatoires et allergiques
US12/858,940 Continuation US20100311706A1 (en) 2002-02-04 2010-08-18 Method of treatment of allergic rhinitis

Publications (1)

Publication Number Publication Date
WO2003066024A1 true WO2003066024A1 (fr) 2003-08-14

Family

ID=27732225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/000504 WO2003066024A1 (fr) 2000-08-05 2003-02-04 Formulation pharmaceutique comprenant une suspension aqueuse d'un derive d'androstane pour le traitement d'etats inflammatoires et allergiques

Country Status (6)

Country Link
US (5) US6858596B2 (fr)
EP (2) EP1478340B1 (fr)
JP (1) JP4838493B2 (fr)
AU (1) AU2003244506A1 (fr)
ES (1) ES2699507T3 (fr)
WO (1) WO2003066024A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010537B2 (en) 2010-10-12 2018-07-03 Chiesi Farmaceutici S.P.A. Clevidipine emulsion formulations containing antimicrobial agents
US11103490B2 (en) 2010-10-12 2021-08-31 Chiesi Farmaceutici S.P.A. Clevidipine emulsion formulations containing antimicrobial agents

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
JP2004505990A (ja) 2000-08-05 2004-02-26 グラクソ　グループ　リミテッド 抗炎症剤としての１７β−カルボチオエート−１７α−アリールカルボニルオキシルオキシアンドロスタン誘導体
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
DE10119718A1 (de) * 2001-04-21 2002-10-31 Boehringer Ingelheim Pharma Verfahren zur kontinuierlichen Herstellung inhalierfähiger Arzneistoffe, Vorrichtung zur Durchführung des Verfahrens und nach diesem Verfahren hergestellter Arzneistoff
ES2314052T3 (es) 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
EP1395604B1 (fr) * 2001-06-12 2008-06-25 Glaxo Group Limited 17 alpha esters heterocycliques anti-inflammatoires de derives de 17 beta carbothioate androstane
GB0125259D0 (en) * 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
WO2009150101A1 (fr) * 2008-06-09 2009-12-17 Glaxo Group Limited Compositions pharmaceutiques renfermant du n-[2-((2r)-2-{[4-[(4-chlorophényl)méthyl]-l-oxo-2(1h)- phtalazinyl]méthyl}-l-pyrrolidinyl)éthyl]-4-(méthyloxy)butanamide
US8642069B2 (en) * 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
SG175330A1 (en) 2009-04-23 2011-11-28 Theravance Inc DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
US9290698B2 (en) 2010-07-15 2016-03-22 Battelle Memorial Institute Biobased polyols for potential use as flame retardants in polyurethane and polyester applications
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
EA028809B1 (ru) * 2012-05-09 2018-01-31 Вестерн Юниверсити Оф Хелт Сайенсиз Пролипосомальные композиции для доставки тестостерона
ES2722926T3 (es) * 2012-12-17 2019-08-20 Glaxo Group Ltd Combinación de levocabastina y furoato de fluticasona para el tratamiento de condiciones inflamatorias y/o alérgicas
WO2015008205A2 (fr) * 2013-07-13 2015-01-22 Mahesh Kandula Compositions et procédés de traitement de maladies respiratoires
EP3509592A4 (fr) 2016-09-09 2020-07-22 Cutispharma, Inc. Suspensions et diluants pour le métronidazole et le baclofène
JPWO2019235616A1 (ja) 2018-06-08 2021-06-17 東興薬品工業株式会社 フルチカゾンフランカルボン酸エステル点鼻組成物
US11756656B2 (en) 2018-06-14 2023-09-12 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335121A (en) * 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
WO2000038811A1 (fr) * 1998-12-24 2000-07-06 Glaxo Group Limited Appareil et procede de preparation de particules cristallines
WO2002012265A1 (fr) * 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYLE) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYLE-3-OXO-ANDROST-1,4,-DIENE-17-ACIDE CARBOTHIOIQUE S-FLUOROMETHYLE ESTER UTILISE COMME AGENT ANTI INFLAMMATOIRE
WO2002066422A1 (fr) * 2001-02-14 2002-08-29 Glaxo Group Limited Derives de phenethanolamine pour le traitement de maladies respiratoires
US20020165211A1 (en) * 2000-08-05 2002-11-07 Keith Biggadike Formulation containing anti-inflammatory androstane derivative
US20020173496A1 (en) * 2000-08-05 2002-11-21 Keith Biggadike Formulation containing novel anti-inflammatory androstane derivative
US20020177581A1 (en) * 2000-08-05 2002-11-28 Keith Biggadike Novel anti-inflammatory androstane derivative
WO2003013427A2 (fr) * 2001-08-03 2003-02-20 Smithkline Beecham Corporation Procede de preparation de derives de fluticasone

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR580494A (fr) 1923-07-10 1924-11-07 Const Metalliques Schiltigheim Procédé d'établissement des buses d'aération ou autres tuyaux
US2837464A (en) * 1955-01-11 1958-06-03 Schering Corp Process for production of dienes by corynebacteria
DE1059906B (de) 1954-10-05 1959-06-25 Scherico Ltd Verfahren zur Herstellung von 1, 4-Pregnadienen
US3067197A (en) * 1961-04-26 1962-12-04 Pfizer & Co C 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
GB1158492A (en) * 1966-02-09 1969-07-16 Boots Pure Drug Co Ltd Improvements in Acylated Steroids
US3639434A (en) * 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
IT1061787B (it) 1967-03-01 1983-04-30 Vismara Francesco Spa Miglioramenti relativi alla preparazione di 17 benzoato di betametazone
GB1227992A (fr) 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
US3557694A (en) * 1969-04-21 1971-01-26 Burroughs Corp Print head latching mechanism
IT1034011B (it) * 1969-06-26 1979-09-10 Vister Vismara Terapeutici S P Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato
GB1384372A (en) 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
US3828080A (en) * 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
US3989686A (en) 1972-06-15 1976-11-02 Glaxo Laboratories Limited Anaesthetic steroids of the androstane series and process for preparing same
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
GB1440063A (en) * 1972-08-11 1976-06-23 Glaxo Lab Ltd 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids
US3881894A (en) * 1972-10-05 1975-05-06 George R Onufer Vapor emission control system and method
DE2336693A1 (de) 1973-07-19 1975-02-06 Nassheuer Ind Ofenbau Jean Strahlheizrohr
GB1517278A (en) 1974-08-30 1978-07-12 Glaxo Lab Ltd Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
US3969686A (en) * 1975-03-26 1976-07-13 Xerox Corporation Beam collimation using multiple coupled elements
YU54476A (en) * 1975-03-31 1982-05-31 Taisho Pharmaceutical Co Ltd Process for obtaining 17-ester 21-halo-pregnane
DE2538569A1 (de) 1975-08-29 1977-03-03 Siemens Ag Verfahren zur metallisierung von duroplasten
CH628355A5 (de) * 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4263289A (en) * 1978-04-05 1981-04-21 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4261984A (en) * 1978-04-05 1981-04-14 Syntex (U.S.A.) Inc. 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes
US4187301A (en) * 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
US4188385A (en) * 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
US4198403A (en) 1978-04-05 1980-04-15 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes
DE2817988A1 (de) * 1978-04-25 1979-11-08 Hoechst Ag Corticoid 17-alkylcarbonate und verfahren zu deren herstellung
US4310466A (en) * 1979-08-31 1982-01-12 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4267173A (en) * 1979-11-05 1981-05-12 Schering Corporation Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor
US4377389A (en) 1979-12-12 1983-03-22 Foster Grant Corporation Dip dyeing of plastic articles and the dye bath composition thereof
CY1291A (en) 1980-02-15 1985-10-18 Glaxo Group Ltd Androstane 17 beta carbothioates
ZA814440B (en) 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
SE449106B (sv) 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
EP0057401B1 (fr) 1981-02-02 1984-08-01 Schering Corporation Esters aromatiques hétérocycliques de stéroides, leur préparation et compositions pharmaceutiques les contenant
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
EP0179583A1 (fr) 1984-10-04 1986-04-30 Merck & Co. Inc. Système pour augmenter la vitesse de dissolution dans l'eau et la solubilité de médicaments peu solubles
US4861765A (en) * 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
ZA872389B (en) 1987-04-02 1987-11-25 Advanced Polymer Systems Inc Composition and method for delivering a steroid active ingredient
US4964069A (en) 1987-05-12 1990-10-16 International Business Machines Corporation Self adjusting video interface
EP0334853B1 (fr) 1987-10-13 1993-06-09 BODOR, Nicholas S. Steroides legers ayant une activite anti-inflammatoire
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5202316A (en) * 1989-03-22 1993-04-13 Roussel Uclaf N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines
FR2644788B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
JPH07116215B2 (ja) 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
EP0477195A1 (fr) 1989-06-16 1992-04-01 The Upjohn Company Composes du type suramine et steroides angiostatiques inhibiteurs de l'angiogenese
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
DK0572549T3 (da) 1991-02-21 2003-01-06 Smithkline Beecham Corp Behandling af ikke-småcellet lungecarcinom
GB9103764D0 (en) 1991-02-22 1991-04-10 Glaxo Group Ltd Compositions
US5250293A (en) * 1991-04-22 1993-10-05 Gleich Gerald J Method for the treatment of hypersensitivity diseases by administration of anionic polymers
TW247878B (fr) 1991-07-02 1995-05-21 Takeda Pharm Industry Co Ltd
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
CA2156408C (fr) 1993-03-17 2005-02-15 Daniel C. Duan Formulation d'aerosol contenant un agent dispersant
DE4328819A1 (de) 1993-08-27 1995-03-02 Hoechst Ag Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE4333920A1 (de) * 1993-10-05 1995-04-13 Hoechst Ag Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
IL109656A (en) 1994-05-15 1998-02-22 Chemagis Ltd Process for the manufacture of androstane - 17 - carbothioates and androstane - 17 - carbothioates prepared thereby
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
AR002009A1 (es) 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
JPH08291073A (ja) 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法
JPH08291072A (ja) 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 吸入用粉末製剤用結晶とその製造方法
DE19528145A1 (de) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
GB9521696D0 (en) 1995-10-23 1996-01-03 Bayer Ag Combination of LTD4 receptor antagonists with glucocorticosteriods
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5792758A (en) 1995-12-08 1998-08-11 G. D. Searle & Co. Steroid nitrite ester derivatives useful as anti-inflammatory drugs
US5707984A (en) 1995-12-08 1998-01-13 G. D. Searle & Co. Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
SK89198A3 (en) 1995-12-29 1999-03-12 Glaxo Group Ltd Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives
US5985862A (en) 1996-05-02 1999-11-16 G.D. Searle & Co. Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
BR9709650A (pt) 1996-06-04 1999-08-10 Procter & Gamble Aerosol nasal contendo um esteróide intransal e um anti-histamínico
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
WO1998034598A2 (fr) 1997-02-07 1998-08-13 Gist-Brocades B.V. Formulations homogenes sous forme de granules destinees a la technologie d'aspiration des doses
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
PT1003501E (pt) 1997-04-02 2005-07-29 Brigham & Womens Hospital Utilizacao de um agente para reduzir o risco de doencas cardiovasculares
AU8439998A (en) 1997-06-30 1999-01-25 Glaxo Group Limited Compounds
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
SE9704833D0 (sv) 1997-12-22 1997-12-22 Astra Ab New formulation
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6261539B1 (en) 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
JP2002532811A (ja) * 1998-12-17 2002-10-02 株式会社ソニー・コンピュータエンタテインメント 楽音データ生成装置および方法、並びに該方法を提供する媒体
AU3703900A (en) 1999-02-24 2000-09-14 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
WO2000057401A1 (fr) 1999-03-24 2000-09-28 Glenayre Electronics, Inc. Calcul et quantification de formes d'impulsions d'excitation voisees, dans le codage predictif de la parole
EP1175383B1 (fr) 1999-04-30 2018-03-14 Pfizer Products Inc. Glucocorticoide recepteur modulateurs
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB9918559D0 (en) * 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
JP2003508453A (ja) 1999-08-31 2003-03-04 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アテローム性動脈硬化疾患の予防における診断的ツールとしての全身性炎症マーカー
ATE363074T1 (de) 1999-09-14 2007-06-15 Xenoport Inc Substrate und screeningverfahren für transportproteine
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
CN1441790A (zh) 2000-01-28 2003-09-10 罗姆和哈斯公司 增强性质的药物
US20020133032A1 (en) 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0017988D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Novel process
US20020037877A1 (en) 2000-07-26 2002-03-28 Alcon Universal Ltd. Pharmaceutical suspension compositions lacking a polymeric suspending agent
US6858593B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
AR032362A1 (es) 2000-08-14 2003-11-05 Glaxo Group Ltd Formulacion topica estable de una emulsion de aceite en agua y proceso para su preparacion
IL155092A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
JP2004512359A (ja) 2000-10-31 2004-04-22 ベーリンガー　インゲルハイム　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング　ウント　コンパニー　コマンディトゲゼルシャフト 抗コリン作用薬及びコルチコステロイドをベースとする新規医薬組成物
US7214672B2 (en) 2000-12-22 2007-05-08 Nippon Shinyaku Co., Ltd. Preventives/remedies for inflammatory airway diseases
US20020132803A1 (en) 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AU2002303425A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
ES2314052T3 (es) 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
EP1395604B1 (fr) 2001-06-12 2008-06-25 Glaxo Group Limited 17 alpha esters heterocycliques anti-inflammatoires de derives de 17 beta carbothioate androstane
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
ATE489103T1 (de) 2001-10-26 2010-12-15 Scripps Research Inst Gezielte thrombose durch gewebefaktor polypeptiden
CN1613012A (zh) 2001-11-05 2005-05-04 布赖汉姆妇女医院 可溶的cd40l(cd154)作为动脉粥样硬化的疾病的先兆标记
WO2003042229A1 (fr) 2001-11-12 2003-05-22 Glaxo Group Limited Esters heterocycliques non aromatiques de furan-2-one esters de 17 $g(b) carboxyl ou 17 $g(b) carbothio glucocorticoides
GB0127160D0 (en) 2001-11-12 2002-01-02 Glaxo Group Ltd Novel compounds
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
WO2003072592A1 (fr) 2002-01-15 2003-09-04 Glaxo Group Limited 17 alpha esters cycloalkyle/cycloalcenyle d'alkyle ou haloalkyle-androst-4-en-3-on-11 beta, 17 alpha-diol 17 beta-carboxylates comme agents anti-inflammatoires
WO2003062259A2 (fr) 2002-01-21 2003-07-31 Glaxo Group Limited Nouveaux composes
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
JP3691459B2 (ja) * 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
GB0217504D0 (en) 2002-07-29 2002-09-04 Novartis Ag Organic compounds
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335121A (en) * 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
WO2000038811A1 (fr) * 1998-12-24 2000-07-06 Glaxo Group Limited Appareil et procede de preparation de particules cristallines
WO2002012265A1 (fr) * 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYLE) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYLE-3-OXO-ANDROST-1,4,-DIENE-17-ACIDE CARBOTHIOIQUE S-FLUOROMETHYLE ESTER UTILISE COMME AGENT ANTI INFLAMMATOIRE
WO2002012266A1 (fr) * 2000-08-05 2002-02-14 Glaxo Group Limited Derives de 17-beta-carbothioate-17-alpha-arylcarbonyloxyloxy androstane utilises comme anti-inflammatoires
US20020165211A1 (en) * 2000-08-05 2002-11-07 Keith Biggadike Formulation containing anti-inflammatory androstane derivative
US20020173496A1 (en) * 2000-08-05 2002-11-21 Keith Biggadike Formulation containing novel anti-inflammatory androstane derivative
US20020177581A1 (en) * 2000-08-05 2002-11-28 Keith Biggadike Novel anti-inflammatory androstane derivative
WO2002066422A1 (fr) * 2001-02-14 2002-08-29 Glaxo Group Limited Derives de phenethanolamine pour le traitement de maladies respiratoires
WO2003013427A2 (fr) * 2001-08-03 2003-02-20 Smithkline Beecham Corporation Procede de preparation de derives de fluticasone

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010537B2 (en) 2010-10-12 2018-07-03 Chiesi Farmaceutici S.P.A. Clevidipine emulsion formulations containing antimicrobial agents
US11103490B2 (en) 2010-10-12 2021-08-31 Chiesi Farmaceutici S.P.A. Clevidipine emulsion formulations containing antimicrobial agents

Also Published As

Publication number Publication date
EP1478340B1 (fr) 2018-09-12
AU2003244506A1 (en) 2003-09-02
US20050164996A1 (en) 2005-07-28
US6858596B2 (en) 2005-02-22
US20120142651A1 (en) 2012-06-07
US20100311706A1 (en) 2010-12-09
EP1478340A1 (fr) 2004-11-24
ES2699507T3 (es) 2019-02-11
US20050020549A1 (en) 2005-01-27
EP3510994A1 (fr) 2019-07-17
JP4838493B2 (ja) 2011-12-14
JP2005521673A (ja) 2005-07-21
US20020165211A1 (en) 2002-11-07
US7541350B2 (en) 2009-06-02

Similar Documents

Publication Publication Date Title
EP1478340B1 (fr) Formulation pharmaceutique comprenant une suspension aqueuse d'un dérivé d'androstane pour le traitement d'états inflammatoires et allergiques
US6787532B2 (en) Formulation containing anti-inflammatory androstane derivatives
EP1471896B1 (fr) Preparations pour inhalation
US6777400B2 (en) Anti-inflammatory androstane derivative compositions
EP2363121A1 (fr) Formulation pharmaceutique pour administrant par inhalation contenant un dérivé d'androstane et un agoniste des récepteurs adrénergiques bêta-2 pour traiter des états inflammatoires et allergiques
US6858593B2 (en) Anti-inflammatory androstane derivative compositions
US6777399B2 (en) Anti-inflammatory androstane derivative compositions
US7531528B2 (en) Formulation containing anti-inflammatory androstane derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003737365

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003565449

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003737365

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10502902

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载